title: Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy.
abstract: Enhanced and targeted drug delivery using biodegradable microspheres is emerging as a promising approach for cancer therapy. The main objective of the present research was to formulate, characterize, and evaluate iron oxide (magnetic) containing a bovine serum albumin-based microsphere drug delivery system, capable of efficiently delivering sulforaphane, a histone deacetylase inhibitor, for an extended period of time in vivo. Magnetic microspheres were prepared by spray-drying and characterized for their physicochemical properties and dissolution profile. Further, they were evaluated for therapeutic efficacy in in vitro and in vivo systems. In vitro studies in B16 melanoma cells revealed that there was about 13%-16% more inhibition of cell viability when either 30 μM or 50 μM of sulforaphane was used with iron oxide in the polymeric carrier. Data from in vivo studies in C57BL/6 mice revealed that the magnetic microspheres (localized to the tumor site with the help of a strong magnet) inhibited 18% more tumor growth as compared with sulforaphane in solution. In addition, there was a 40% reduction in histone deacetylation levels in mice treated with iron oxide microspheres containing sulforaphane. Thus, magnetic microspheres are shown to be an effective drug delivery system for anticancer drugs.
authors: Department of Pharmaceutical Sciences, College of Pharmacy, Chicago State University, Chicago, IL 60628, USA.
authors: Gerald G
authors: GG
authors: Enriquez
authors: Syed A A
authors: SA
authors: Rizvi
authors: Martin J
authors: MJ
authors: D'Souza
authors: Duc P
authors: DP
authors: Do
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D002470:Cell Survival; D004337:Drug Carriers / Q000737:chemistry* / Q000493:pharmacokinetics; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D006655:Histone Deacetylases / Q000378:metabolism; D017879:Isothiocyanates / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D058185:Magnetite Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D051379:Mice; D008810:Mice, Inbred C57BL; D008863:Microspheres; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D012710:Serum Albumin, Bovine; D013454:Sulfoxides
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D056572:Histone Deacetylase Inhibitors; D017879:Isothiocyanates; D058185:Magnetite Nanoparticles; D013454:Sulfoxides; D012710:Serum Albumin, Bovine; D006655:Histone Deacetylases; C016766:sulforaphane
keywords: delivery system; epigenetic therapy; histone deacetylase inhibitor; iron oxide; microspheres; sulforaphane
references: Nature. 2004 May 27;429(6990):457-63
references: 15164071
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: J Control Release. 2012 Jan 10;157(1):4-28
references: 21959118
references: J Drug Target. 2003 Apr;11(3):139-49
references: 13129824
references: Int J Pharm. 2004 Jun 11;277(1-2):19-24
references: 15158965
references: J Microencapsul. 2008 Dec;25(8):577-83
references: 19003560
references: J Immunol. 2012 Aug 15;189(4):1946-54
references: 22778395
references: Mol Pharm. 2008 Mar-Apr;5(2):316-27
references: 18217714
references: Oncogene. 2003 Sep 29;22(42):6479-83
references: 14528271
references: Blood. 2004 Mar 1;103(5):1635-40
references: 14604977
references: J Biomed Mater Res. 1994 Aug;28(8):901-8
references: 7983088
references: J Agric Food Chem. 2006 Dec 13;54(25):9370-6
references: 17147420
references: J Nutr. 2009 Dec;139(12):2393-6
references: 19812222
references: J Control Release. 2010 Jul 1;145(1):17-25
references: 20307599
references: Nanomedicine (Lond). 2012 Mar;7(3):447-57
references: 22385201
references: J Control Release. 2002 Feb 19;79(1-3):29-40
references: 11853916
references: Dermatol Clin. 2012 Jul;30(3):355-61
references: 22800543
references: J Surg Res. 2001 Feb;95(2):200-6
references: 11162046
references: Chem Soc Rev. 2012 Jun 7;41(11):4306-34
references: 22481569
references: Chemistry. 2012 Dec 3;18(49):15676-82
references: 23080514
references: J Drug Target. 2007 Feb;15(2):140-5
references: 17365285
references: APMIS. 2007 Oct;115(10):1039-59
references: 18042143
references: Nat Rev Drug Discov. 2006 Sep;5(9):769-84
references: 16955068
references: Nanomedicine (Lond). 2010 Nov;5(9):1459-66
references: 21128726
references: Curr Cancer Drug Targets. 2011 Feb;11(2):184-9
references: 21158723
references: Langmuir. 2007 Nov 20;23(24):12329-36
references: 17960940
references: Cancer Biother Radiopharm. 2004 Dec;19(6):764-9
references: 15665625
references: Colloids Surf B Biointerfaces. 2004 Jul 1;36(1):35-42
references: 15261021
references: Br J Radiol. 2012 Feb;85(1010):101-13
references: 22010024
references: Biol Chem. 2011 Nov;392(11):955-60
references: 21848508
references: Pharm Res. 2008 Aug;25(8):1815-21
references: 18373181
references: Nanomedicine (Lond). 2008 Dec;3(6):831-44
references: 19025457
references: J Microencapsul. 2007 Jun;24(4):337-48
references: 17497387
references: Drug Dev Ind Pharm. 2007 Feb;33(2):133-9
references: 17454044
references: J Microencapsul. 2009 Dec;26(8):692-700
references: 19888878
references: Chem Res Toxicol. 1997 Nov;10(11):1228-33
references: 9403174
references: Cancer Res. 2005 Dec 15;65(24):11631-8
references: 16357174
references: Mol Cancer Ther. 2007 Mar;6(3):1013-21
references: 17339367
references: J Biomed Mater Res B Appl Biomater. 2008 Oct;87(1):189-96
references: 18437713
references: Int J Pharm. 2010 Feb 15;386(1-2):114-21
references: 19922783
references: Epigenomics. 2012 Apr;4(2):163-77
references: 22449188
references: Mol Pharm. 2005 May-Jun;2(3):194-205
references: 15934780
references: Cancer Discov. 2012 May;2(5):405-13
references: 22588878
references: FASEB J. 2006 Mar;20(3):506-8
references: 16407454
references: Cancer Res. 2004 Aug 15;64(16):5767-74
references: 15313918
references: Nature. 2007 May 24;447(7143):396-8
references: 17522671
references: Nucl Med Biol. 1995 Feb;22(2):147-55
references: 7767307
references: Nanomedicine. 2012 Apr;8(3):275-90
references: 21930108
references: CA Cancer J Clin. 2008 Mar-Apr;58(2):97-110
references: 18227410